High-Density Lipoproteins and the Immune System
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
High-density lipoprotein (HDL) plays a major role in vasodilation and in the reduction of low-density lipoprotein (LDL) oxidation, inflammation, apoptosis, thrombosis, and infection; however, HDL is now less functional in these roles under certain conditions. This paper focuses on HDL, its anti-inflammation behavior, and the mechanisms by which HDL interacts with components of the innate and adaptive immune systems. Genome-wide association studies (GWAS) and proteomic studies have elucidated important molecules involved in the interaction between HDL and the immune system. An understanding of these mechanisms is expected to be useful for the prevention and treatment of chronic inflammation due to metabolic syndrome, atherosclerosis, or various autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 2×
“PAMP recognition leads to activation and production of the complement cascade, cytokines, and antimicrobial peptides [20].”
BackgroundBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113 · cited 1×
“A reduced plasma HDL-C level is a factor of metabolic syndrome, which causes obesity and chronic inflammation [82, 83].”
BackgroundEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“In accordance with this evidence, recent randomized prospective study resulted that CETP inhibitor dalcetrapib increased HDL-C levels but did not reduce the risk of recurrent cardiovascular events in patient who had had a recent acute coronary syndrome [93].”
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386 · cited 1×
“This study was supported in part by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.”
MethodVaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response
Garlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota, R., Maccagno, A., Riva, F., Bottazzi, B., Peri, G., et al. (2002) · Nature · doi:10.1038/nature01195 · Cited by 669
Kuo, L. E., Kitlinska, J. B., Tilan, J. U., Li, L., Baker, S. B., Johnson, M. D., Lee, E. W., Burnett, M. S., Fricke, S. T., Kvetnansky, R., et al. (2007) · Nature Medicine · doi:10.1038/nm1611 · Cited by 656
An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm
Bottazzi, B., Doni, A., Garlanda, C., & Mantovani, A. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101305 · Cited by 592 · cited 1×
“These PRRs include c-type lectins, leucin-rich proteins, macrophage scavenger receptors, pentraxins, lipid transferase, integrins, and inflammasome proteins [18, 19].”
BackgroundFrikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Wurfel, M. M., Kunitake, S. T., Lichenstein, H., Kane, J. P., & Wright, S. D. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1025 · Cited by 442 · cited 2×
“Innate immunity consists of a highly regulated immune surveillance system comprising several humoral factors, including soluble PRRs, such as collectins, ficolins, and pentraxins [32, 33], and the complement cascade [34].”
BackgroundGenetic Variant of the Scavenger Receptor BI in Humans
Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317 · cited 1×
“Carriers with a functional mutation in SR-B1 yield higher plasma levels of HDL-C and reduced efflux of cholesterol frommacrophages, but no significant increases in atherosclerosis [90].”
BackgroundMurphy, A. J., Woollard, K. J., Suhartoyo, A., Stirzaker, R. A., Shaw, J., Sviridov, D., & Chin-Dusting, J. P. F. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226258 · Cited by 244
Cai, L., Ji, A., de Beer, F. C., Tannock, L. R., & van der Westhuyzen, D. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci31539 · Cited by 167 · cited 4×
“SR-B1 deficiency results in a reduced rate of survival following sepsis [33].”
BackgroundInfluentialWang, S.-H., Yuan, S.-G., Peng, D.-Q., & Zhao, S.-P. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.07.029 · Cited by 111 · cited 1×
“S1P inhibits forkhead box P3 (FoxP3)+ in regulatory T cells (Tregs) but stimulates the development of Th1 cells [65].”
Background
Cited by
Limonta, G., Mancia, A., Benkhalqui, A., Bertolucci, C., Abelli, L., Fossi, M. C., & Panti, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-52292-5 · Cited by 385
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Functionality of HDL: Antioxidation and Detoxifying Effects
Karlsson, H., Kontush, A., & James, R. W. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-09665-0_5 · Cited by 55
Potential role of anti-inflammatory HDL subclasses in metabolic unhealth/obesity
Tang, H., Xiang, Z., Li, L., Shao, X., Zhou, Q., You, X., Xiong, C., Ning, J., Chen, T., Deng, D., et al. (2021) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2021.1961798 · Cited by 27
The lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
Metadata
- Authors
- Kaji, H.
- Venue
- Journal of Lipids
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-8
- ISSN
- 2090-3030 (ISSN-L)
- 2090-3049
- OpenAlex
- W1971642258
- Cited by
- 79
- References
- 17
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.